Endometrial Cancer Treatment in Hyderabad — Expert Uterine Cancer Care Across 7 Locations

Endometrial Cancer — What It Is and Why It Is Usually Found Early

The uterus is the hollow, pear-shaped organ in the pelvis where a pregnancy develops. Its inner lining — the endometrium — thickens and sheds each month during menstruation. Endometrial cancer develops when cells in this lining begin to grow in an uncontrolled way.

'Uterine cancer' and 'endometrial cancer' are terms that are often used interchangeably, and for most patients they refer to the same disease. The important distinction is:

• Endometrial cancer (adenocarcinoma of the endometrium) — by far the most common type; accounts for about 95% of all uterine cancers; what this page covers.
• Uterine sarcoma — a rarer cancer that develops in the muscle wall of the uterus (the myometrium) rather than the lining; treated differently; relatively uncommon.

Endometrial cancer is highly curable because it almost always causes abnormal bleeding early in its course — well before it has spread beyond the uterus. This is why any unusual vaginal bleeding should never be dismissed or waited out.

Type 1 and Type 2 Endometrial Cancer — Why the Distinction Matters

No local hospital treatment page in Hyderabad currently explains this clinically important distinction — but it directly affects treatment recommendations and prognosis.

What Increases the Risk of Endometrial Cancer?

Most endometrial cancers are linked to factors that increase lifetime oestrogen exposure of the uterine lining. Understanding your personal risk profile helps determine surveillance and family-screening decisions.

• Obesity — the single most important modifiable risk factor; fat tissue converts hormones into oestrogen, which stimulates the uterine lining; women with a BMI above 30 have a significantly higher risk.
• Oestrogen-only hormone replacement therapy — taking oestrogen without progesterone after menopause stimulates the uterine lining without balance; combined HRT (oestrogen + progesterone) does not carry this risk.
• Tamoxifen therapy for breast cancer — tamoxifen reduces breast cancer recurrence but has an oestrogen-like effect on the uterus; women on tamoxifen have 2 to 3 times the baseline risk; annual gynaecologic review is recommended for all long-term tamoxifen users.
• Polycystic ovary syndrome (PCOS) — causes irregular or absent periods, leading to prolonged oestrogen exposure of the uterine lining without regular shedding.
• Late menopause (after age 55) and never having been pregnant — both increase cumulative oestrogen exposure.
• Diabetes — independently associated with increased risk.
• Lynch syndrome (HNPCC) — the most common hereditary cause of endometrial cancer; see dedicated section below.

Symptoms of Endometrial Cancer

Endometrial cancer is unusual among cancers because it almost always causes a clear early symptom. The vast majority of women are diagnosed because of:

• Abnormal vaginal bleeding — the cardinal symptom; this means any vaginal bleeding after menopause (even very light spotting); periods that are heavier than usual or last longer than usual; bleeding between periods.
• Unusual vaginal discharge — watery or blood-tinged discharge, particularly after menopause.
• Pelvic pain or pressure in the lower abdomen.
• Pain during sexual intercourse.
• Unexplained weight loss and fatigue — more commonly associated with advanced disease.

Postmenopausal bleeding is never normal. It does not always mean cancer — there are several benign causes — but it always deserves investigation. CION's gynaecologic oncology team can evaluate postmenopausal bleeding with a transvaginal ultrasound and endometrial biopsy, typically as an outpatient appointment. Speak to a CION specialist if you've experienced any of these symptoms.

Why Patients Choose CION for Endometrial Cancer Treatment in Hyderabad

Ten reasons our patients pick CION — across volume, surgical and brachytherapy expertise, current systemic therapy, and family-screening support.

How Is Endometrial Cancer Diagnosed at CION?

CION's diagnostic pathway begins with the most appropriate first-line test for abnormal vaginal bleeding and progresses through tissue confirmation and accurate staging before any treatment decision is made.

1. Transvaginal Ultrasound

   The first investigation for abnormal vaginal bleeding. An ultrasound probe placed inside the vagina measures the thickness of the uterine lining. A thickened endometrium — typically above 4 to 5mm in a postmenopausal woman — raises suspicion and prompts further investigation. The ultrasound also identifies any obvious masses within the uterus.

2. Endometrial Biopsy

   A small sample of tissue is taken from the uterine lining, usually in the clinic under local anaesthesia. This is the definitive test for endometrial cancer — the sample is examined under a microscope to confirm whether cancer cells are present, identify the type (Type 1 or Type 2), and assess the grade. Quick, well tolerated, and avoids general anaesthetic in most cases.

3. Hysteroscopy

   A thin, flexible camera is passed through the cervix into the uterus, allowing direct visualisation of the uterine cavity. Used when the biopsy result is inconclusive or when a specific lesion needs to be sampled under direct vision. A biopsy or curettage can be performed at the same time.

4. Imaging for Staging

   MRI Pelvis shows the depth of tumour invasion into the uterine wall, any extension to the cervix, and pelvic lymph node status — the most important staging scan for endometrial cancer. CT Scan (chest, abdomen, pelvis) checks for distant spread. PET-CT is reserved for selected cases where CT findings are equivocal.

A Test Every Endometrial Cancer Patient Should Have — MSI-H and Lynch Syndrome

This is one of the most clinically important aspects of endometrial cancer management — and no local hospital treatment page in Hyderabad currently explains it.

When an endometrial cancer is diagnosed, a test called MMR (mismatch repair) testing should be performed on every tumour sample. This test looks for whether four specific proteins in the cancer cells are present or absent. Here is why it matters:

• If the test shows a defect (called MSI-H or dMMR — meaning mismatch repair deficient) — the patient may be eligible for pembrolizumab (an immunotherapy medicine) as first-line treatment rather than standard chemotherapy — with significantly better outcomes. An MSI-H result also raises the possibility that the patient has Lynch syndrome, an inherited genetic condition that increases the risk of colorectal and other cancers.
• If the test shows normal mismatch repair (MSS or pMMR) — the patient is not likely to have Lynch syndrome but may still benefit from a specific combination of medicines (described below) if the cancer is advanced.

At CION, MMR testing is arranged as a routine part of the pathological assessment for all endometrial cancer patients at diagnosis.

Lynch Syndrome — Protecting Your Family

Lynch syndrome (also called Hereditary Non-Polyposis Colorectal Cancer or HNPCC) is an inherited gene fault that significantly increases the lifetime risk of several cancers — most importantly colorectal cancer and endometrial cancer. In fact, endometrial cancer is the most common cancer in women with Lynch syndrome.

Approximately 3 to 5% of all endometrial cancers are caused by Lynch syndrome. If MMR testing of the tumour suggests Lynch syndrome, a blood test can confirm whether the patient carries the gene fault. When this is confirmed, it has important implications not just for the patient's own follow-up but for her close family members — parents, siblings, and children each have a 50% chance of carrying the same gene fault, and genetic testing and early surveillance can catch cancers at a much earlier stage.

CION offers genetic counselling and family referral for all patients whose tumour testing raises the possibility of Lynch syndrome.

Endometrial Cancer Staging and Survival Rates

Endometrial cancer is staged using the FIGO (International Federation of Gynaecology and Obstetrics) system. The final stage is confirmed after surgery based on pathological findings — depth of invasion, lymph node status, and tumour type all contribute.

Note: 5-year survival estimates are for endometrial adenocarcinoma at specialist centres. Type 2 tumours (serous and clear cell) have lower stage-specific survival. MSI-H tumours treated with pembrolizumab-based regimens are showing improved outcomes in ongoing trials.

Surgery for Endometrial Cancer — the Primary Treatment

Surgery is the cornerstone of endometrial cancer treatment. For most patients, the operation involves:

• Total hysterectomy — removal of the uterus and cervix.
• Bilateral salpingo-oophorectomy (BSO) — removal of both ovaries and both fallopian tubes; the ovaries themselves produce oestrogen which can stimulate any remaining cancer cells.
• Sentinel lymph node biopsy or full lymphadenectomy — examination of the pelvic lymph nodes; the results directly determine whether adjuvant treatment is needed.

Minimally Invasive Surgery — the Preferred Approach

For the great majority of endometrial cancer patients, this operation is performed laparoscopically or robotically — through several small keyhole incisions in the abdomen. Compared to open surgery, the minimally invasive approach offers:

• A shorter hospital stay — 1 to 2 days rather than 4 to 5.
• Significantly less pain after the operation.
• A faster return to normal activities.
• Reduced risk of wound complications.
• Equivalent cancer control outcomes.

CION's surgical oncology team, led by Dr. Raghavendra Naik (MCh Surgical Oncology, SVIMS), performs laparoscopic hysterectomy and BSO as the standard approach for endometrial cancer surgery in Hyderabad.

Radiation Therapy After Surgery — Vaginal Vault Brachytherapy

After surgery, whether additional treatment is needed depends on the stage, grade, and type of the tumour, as assessed from the removed specimen. The most commonly recommended adjuvant radiation for Stage I endometrial cancer is vaginal vault brachytherapy — a form of internal radiation that no local hospital treatment page in Hyderabad currently explains to patients.

What Is Vaginal Vault Brachytherapy?

After the uterus is removed, the top of the vagina (called the vaginal vault or vaginal cuff) is the most likely site for endometrial cancer to come back locally. Vaginal vault brachytherapy delivers a targeted radiation dose directly to this area — from the inside — to significantly reduce this risk.

The procedure: a small, smooth cylindrical applicator is placed inside the vagina. A radioactive source is briefly introduced through the applicator, spending a few minutes at the vaginal vault and delivering a concentrated dose of radiation precisely where it is needed. The procedure takes about 15 to 30 minutes in total, is done under light sedation or sometimes just with local preparation, and patients go home the same day. Typically 3 sessions are given, spaced 1 to 2 weeks apart.

Vaginal vault brachytherapy has far fewer side effects than full pelvic radiation — the bladder and bowel receive much less dose — making it the preferred option for Stage I intermediate-risk endometrial cancer. Full pelvic external beam radiation is reserved for higher-stage disease where more extensive coverage is needed.

Chemotherapy for Endometrial Cancer

Chemotherapy is used in two situations for endometrial cancer:

• As adjuvant treatment after surgery for Stage III and Stage IVA disease, or for Type 2 (serous/clear cell) tumours — where the risk of distant spread is higher and systemic treatment is needed alongside radiation.
• As the primary treatment for Stage IVB (metastatic) disease, often combined with targeted or immunotherapy medicines.

The standard chemotherapy regimen for endometrial cancer is a combination of two intravenous medicines given every 3 weeks. The combination is well tolerated by most patients and delivered in a day-care setting. Side effects including fatigue, nausea, and temporary hair thinning are monitored and managed throughout treatment.

Can Younger Women Avoid Hysterectomy? — Fertility-Sparing Treatment

Most endometrial cancer patients are postmenopausal women in their 60s. However, a small but growing proportion are diagnosed in younger women who have not yet had children. For carefully selected patients in this group, a fertility-preserving approach may be possible instead of immediate hysterectomy.

The fertility-sparing approach uses high-dose progestins — a type of hormone medicine — to suppress the cancer without removing the uterus. This can be given as:

• Oral tablets (daily high-dose progesterone medicine) — taken for at least 6 months with regular monitoring.
• A hormone-releasing IUD (intrauterine device) — releases progestin locally at the uterine lining with fewer systemic side effects.

Studies show that progestin therapy achieves complete remission (the cancer disappears on repeat biopsy) in a meaningful proportion of eligible patients — though response rates are not 100% and close monitoring is essential. Eligibility is strict:

• Grade 1 (well-differentiated) endometrial cancer only — not recommended for Grade 2 or Grade 3.
• Stage IA only — tumour confined to the uterine lining with no muscle wall invasion.
• No suspicious ovarian lesions on imaging.
• Strong desire to preserve fertility and commitment to 3-monthly repeat biopsies throughout treatment.
• Agreement to proceed to hysterectomy after completing childbearing.

If you are a young woman with early-stage endometrial cancer who has been told hysterectomy is the only option, and you wish to have children, it is worth discussing fertility-sparing eligibility with CION's gynaecologic oncology team before proceeding to surgery.

Hormone Therapy for Advanced or Recurrent Type 1 Endometrial Cancer

For well-differentiated (Grade 1) Type 1 endometrial cancer that has come back or spread, hormone therapy — using progesterone medicines — can control the disease for months to years in patients whose tumour is hormone receptor-positive. It is generally very well tolerated and can be given as oral tablets. Hormone therapy is particularly considered for patients who are not fit for or have already received chemotherapy, and for older patients for whom quality of life preservation is a priority.

Every Case Reviewed by a Specialist Team Before Treatment

At CION, every endometrial cancer case is reviewed by our multidisciplinary team before any treatment plan is finalised:

• MMR / MSI-H testing arranged at diagnosis for all patients — immunotherapy eligibility and Lynch syndrome assessment.
• Type 1 vs Type 2 tumour confirmed from pathology report — adjuvant treatment plan tailored accordingly.
• Minimally invasive hysterectomy (laparoscopic or robotic) as the standard approach for eligible patients.
• Sentinel lymph node biopsy considered for intermediate-risk cases — reducing lymphadenectomy-related morbidity.
• Vaginal vault brachytherapy vs full pelvic radiation decision based on stage and risk factors.
• Fertility-sparing progestin therapy discussed for eligible young patients before any surgical recommendation.
• Advanced disease: pembrolizumab eligibility and targeted combination assessment.
• Lynch syndrome confirmed patients referred for genetic counselling and family screening.
• Tamoxifen-associated endometrial cancer: breast oncology team coordination.
• NCCN and ESMO protocol adherence · digital coordination across all 7 Hyderabad locations.

CION vs National 1-Year Survival Rates*

CION patients consistently see higher 1-year survival than the national average across major cancers — a function of multidisciplinary tumour-board review, NCCN/ESMO adherence, and access to current systemic therapy.

*1-year survival rates. National data sourced from ICMR / National Cancer Registry Programme (NCRP). Endometrial-specific Indian survival data is limited; gynaecologic survival outcomes at specialist centres generally exceed national averages.

Endometrial Cancer Treatment Cost in Hyderabad

Treatment costs vary by stage, surgical approach, and whether adjuvant treatment is required:

Costs are indicative. A personalised cost estimate is provided following your initial oncology consultation at CION.

Financial Support Options

• EMI Facility — flexible instalment-based payment options available for all patients.
• Private Health Insurance — CION works with all major TPAs for cashless hospitalisation.

Endometrial Cancer Care Near You — In Hyderabad & Beyond

CION operates 35+ centres across Telangana and Andhra Pradesh. Find your nearest endometrial cancer specialist or explore care options in your city.

Endometrial Cancer Care in Hyderabad — by Location

Endometrial Cancer Care Beyond Hyderabad

Travelling for treatment? We may have a centre right where you are — across Telangana and Andhra Pradesh.

Not seeing your city? Call 18002028726 — we'll connect you to the nearest CION centre or arrange a teleconsultation.

Consult an Endometrial Cancer Specialist Today

Whether you've experienced postmenopausal bleeding, received a new diagnosis, or want a second opinion — we can see you this week.

Frequently Asked Questions

Common questions about endometrial cancer treatment in Hyderabad — answered by CION's gynaecologic oncology team.

Disclaimer: This content is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified oncologist for guidance specific to your medical condition. The information on this page is periodically reviewed and updated by CION's medical team in accordance with current clinical guidelines.